Aclarion Secures U.S. Patent Covering Machine Learning–Based Platform For Analyzing Magnetic Resonance Spectroscopy Data

• Patent covers use of AI in workflows of future products to accelerate company's ability to scale and enhance already strong gross margins
   
• Expands intellectual property portfolio to 64 issued and pending patents worldwide, strengthening long-term competitive moat
   

BROOMFIELD, Colo., April 16, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the issuance of U.S. Patent #12,601,803, titled "System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain," covering its machine learning–based platform for analyzing magnetic resonance spectroscopy (MRS) data.

Aclarion's cloud-based platform, Nociscan, converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine. The newly issued patent strengthens Aclarion's ability to scale by protecting its use of AI in future versions of the platform to further automate biomarker identification, accelerate report generation and reduce manual quality reviews.